RS 17053 hydrochlorideα1A-adrenoceptor antagonist, novel and selective CAS# 169505-93-5 |
- Perindopril Erbumine
Catalog No.:BCC3586
CAS No.:107133-36-8
- Losartan Potassium (DuP 753)
Catalog No.:BCC1080
CAS No.:124750-99-8
- Candesartan
Catalog No.:BCC2558
CAS No.:139481-59-7
- Telmisattan
Catalog No.:BCC3863
CAS No.:144701-48-4
- Imidapril HCl
Catalog No.:BCC3792
CAS No.:89396-94-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 169505-93-5 | SDF | Download SDF |
| PubChem ID | 9824953 | Appearance | Powder |
| Formula | C24H30Cl2N2O2 | M.Wt | 449.42 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 125 mg/mL (278.14 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 1-(5-chloro-1H-indol-3-yl)-N-[2-[2-(cyclopropylmethoxy)phenoxy]ethyl]-2-methylpropan-2-amine;hydrochloride | ||
| SMILES | CC(C)(CC1=CNC2=C1C=C(C=C2)Cl)NCCOC3=CC=CC=C3OCC4CC4.Cl | ||
| Standard InChIKey | QFOPFGRPNPCPBX-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C24H29ClN2O2.ClH/c1-24(2,14-18-15-26-21-10-9-19(25)13-20(18)21)27-11-12-28-22-5-3-4-6-23(22)29-16-17-7-8-17;/h3-6,9-10,13,15,17,26-27H,7-8,11-12,14,16H2,1-2H3;1H | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | α1A-adrenoceptor antagonist, with very high affinity for α1A receptors (pKi and pA2 estimates of 9.1 - 9.9) and a 30 - 100 fold selectivity over the α1B and α1D subtypes (pKi and pA2 estimates 7.7 - 7.8). |
RS 17053 hydrochloride Dilution Calculator
RS 17053 hydrochloride Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.2251 mL | 11.1255 mL | 22.2509 mL | 44.5018 mL | 55.6273 mL |
| 5 mM | 0.445 mL | 2.2251 mL | 4.4502 mL | 8.9004 mL | 11.1255 mL |
| 10 mM | 0.2225 mL | 1.1125 mL | 2.2251 mL | 4.4502 mL | 5.5627 mL |
| 50 mM | 0.0445 mL | 0.2225 mL | 0.445 mL | 0.89 mL | 1.1125 mL |
| 100 mM | 0.0223 mL | 0.1113 mL | 0.2225 mL | 0.445 mL | 0.5563 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
RS 17053 hydrochloride is a novel and selective α1A-adrenoceptor antagonist [1].
α1A-adrenoceptor are widely distributed and activated either by epinephrine released from the adrenal medulla or by norepinephrine released from sympathetic nerve terminals. α1A-adrenoceptor mediate a variety of functions, including cardiac stimulation, contraction of smooth muscle, activation of hepatic gluconeogenesis， glycogenolysis, cellular proliferation and apoptosis.
In rat several tissues, RS-17053 had high affinity for the α1A -adrenoceptor and a 30 ~100-fold selectivity over the α1B - and the α1D -adrenoceptor subtypes [1]. RS 17053 had over 100-fold lower affinity for the α1A -adrenoceptor mediating contraction of the rat portal vein (pKB 7.1) and human prostate (pKB 7.1) compared with its affinity for the α1A -adrenoceptor in the rat epididymal vas deferens or the expressed α1A -clone. Therefore, RS 17053 may distinguish between subtypes of the α1A -adrenoceptor in the rat portal vein and human prostate compared with those in the rat epididymal vas deferens or the expressed α1A -clones [2].
References:
[1]. Ford AP, Arredondo NF, Blue DR Jr, et al. RS 17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-α,α-dimethyl-1H-indole-3-ethanamine hydrochloride, a selective α1A-adrenoceptor antagonist, displays low affinity for functional α1-adrenoceptors in human prostate: implications for adrenoceptor classification. Mol Pharmacol, 1996, 49(2): 209-215.
[2]. Marshall I, Burt RP, Green GM, et al. Different subtypes of α1A-adrenoceptor mediating contraction of rat epididymal vas deferens, rat hepatic portal vein and human prostate distinguished by the antagonist RS 17053. Br J Pharmaco, 1996, 119(2): 407-415.
- Boc-N-Me-Ala-OH
Catalog No.:BCC3209
CAS No.:16948-16-6
- 3β,7β,15β-trihydroxy-11-oxo-lanosta-8-en-24->20 lactone
Catalog No.:BCC8643
CAS No.:1694587-15-9
- Boc-D-Leu-OH.H2O
Catalog No.:BCC3409
CAS No.:16937-99-8
- Boc-D-Orn(Z)-OH
Catalog No.:BCC3431
CAS No.:16937-92-1
- Nebivolol hydrochloride
Catalog No.:BCC9099
CAS No.:169293-50-9
- Ro 25-6981
Catalog No.:BCC4158
CAS No.:169274-78-6
- Fmoc-Phe(4-F)-OH
Catalog No.:BCC3220
CAS No.:169243-86-1
- Dihydropedicin
Catalog No.:BCN4692
CAS No.:169234-89-3
- Trametol
Catalog No.:BCN6924
CAS No.:169217-47-4
- MTPG
Catalog No.:BCC6820
CAS No.:169209-66-9
- MPPG
Catalog No.:BCC6818
CAS No.:169209-65-8
- MSPG
Catalog No.:BCC6819
CAS No.:169209-64-7
- Protostemotinine
Catalog No.:BCN8314
CAS No.:169534-85-4
- IRL-2500
Catalog No.:BCC7192
CAS No.:169545-27-1
- Fmoc-Ala(4-pyridyl)-OH
Catalog No.:BCC3327
CAS No.:169555-95-7
- Otosenine
Catalog No.:BCN2107
CAS No.:16958-29-5
- Florosenine
Catalog No.:BCN2108
CAS No.:16958-30-8
- Floridanine
Catalog No.:BCN2103
CAS No.:16958-31-9
- Floricaline
Catalog No.:BCN2104
CAS No.:16958-32-0
- Deracoxib
Catalog No.:BCC4108
CAS No.:169590-41-4
- Celecoxib
Catalog No.:BCC1099
CAS No.:169590-42-5
- Odoratone
Catalog No.:BCN1105
CAS No.:16962-90-6
- Trichosanatine
Catalog No.:BCN1818
CAS No.:169626-16-8
- Isodonal
Catalog No.:BCN3390
CAS No.:16964-56-0
RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification.[Pubmed:8632751]
Mol Pharmacol. 1996 Feb;49(2):209-15.
Norepinephrine (NE) contracts smooth muscle cells within the human lower urinary tract (LUT) (bladder neck, prostate, and urethra). Receptor distribution and pharmacological evidence have implicated activation of alpha 1A-adrenoceptors. We disclose the pharmacological properties of the novel, selective alpha 1A-adrenoceptor antagonist N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro- alpha,alpha-dimethyl-1H-indole-3-ethanamine hydrochloride (RS-17053) and examine critically the pharmacological identity of the alpha 1-adrenoceptor mediating contractions to NE in human LUT tissues. In several tissues from rat and cloned adrenoceptors, RS-17053 displayed high affinity for the alpha 1A-adrenoceptor (pKi and pA2 estimates of 9.1-9.9) and a 30-100-fold selectivity over the alpha 1B- and the alpha 1D-adrenoceptor subtypes (pK1 and pA2 estimates of 7.7-7.8). However, in isolated smooth muscle preparations from human LUT tissues, RS-17053 antagonized responses to NE only at high concentrations. Estimates of affinity (pA2) at alpha 1-adrenoceptors mediating NE-induced contractions were 7.5 in prostatic periurethral longitudinal smooth muscle (compared with 8.6 for prazosin), 6.9 in anterior fibromuscular stroma (prazosin, 8.9), and 7.1 in bladder neck (prazosin, 8.5). These findings indicate that contractile responses to NE in human LUT tissues are mediated by a receptor displaying pharmacological properties that are clearly different from those of the defined alpha 1A-adrenoceptor and raise the possibility that multiple forms of the alpha 1A-adrenoceptor may exist in human LUT that are discriminated by RS-17053. In this regard, the affinity estimates obtained with RS-17053 and other alpha 1-adrenoceptor antagonists in human LUT tissues are identical to those described for the putative alpha 1L-adrenoceptor.
Different subtypes of alpha 1A-adrenoceptor mediating contraction of rat epididymal vas deferens, rat hepatic portal vein and human prostate distinguished by the antagonist RS 17053.[Pubmed:8886428]
Br J Pharmacol. 1996 Sep;119(2):407-15.
1. The alpha 1-adrenoceptor subtype mediating contraction of the rat hepatic portal vein to phenylephrine was characterized by use of competitive antagonists previously shown to have selectivity between the expressed alpha 1-subtype clones. Prazosin competitively antagonized the phenylephrine contractions with a pA2 value of 9.2, as did WB 4101 (pA2 9.4), 5-methyl urapidil (pA2 8.6), indoramin (pA2 8.4) and BMY 7378 (pA2 6.5). 2. The pA2 values on the rat portal vein correlated highly with their previously published pA2 values for the alpha 1A-adrenoceptors mediating contraction of the rat epididymal vas deferens and human prostate and poorly with those for the alpha 1B- and alpha 1D-adrenoceptors mediating contraction of the rat spleen and aorta, respectively. The antagonist pA2 values on the rat portal vein correlated highly with their previously published pK1 values for the expressed alpha 1a-clone and poorly with those for the expressed alpha 1b- and alpha 1d-clones. Therefore the results show that contraction of the rat portal vein to phenylephrine is mediated by alpha 1A-adrenoceptors. 3. The novel alpha 1-adrenoceptor antagonist RS 17053 had a relatively high affinity for the alpha 1A-adrenoceptors mediating contraction of the rat epididymal vas deferens (pA2 9.5) compared with the alpha 1B-adrenoceptors in the rat spleen (pA2 7.2) or the alpha 1D-adrenoceptors in the rat aorta (pKB 7.1), in agreement with its selectivity for the expressed alpha 1a-clone. However, RS 17053 had over 100 fold lower affinity for the alpha 1A-adrenoceptors mediating contraction of the rat portal vein (pKB 7.1) and human prostate (pKB 7.1) compared with its affinity for the alpha 1A-adrenoceptors in the rat epididymal vas deferens or the expressed alpha 1a-clone. 4. The difference in affinity of RS 17053 between the rat epididymal vas deferens and rat portal vein cannot be explained by a species difference in the receptor. Therefore RS 17053 may distinguish between subtypes of the alpha 1A-adrenoceptor in the rat portal vein and human prostate compared with those in the rat epididymal vas deferens or the expressed alpha 1a-clone.
